From patients, to patients…..
Since being granted a MC Import license in late 2020, Sativite has sourced a range of premium Medicinal Cannabis products from strategic partners around the globe – including Jamaica, Canada and the United states.
“These premium products have enabled Sativite to develop its patient access market during this pre-cultivation phase”
Mike Cleary – CEO
From humble beginnings, our growth has been phenomenal as patients sample our awardwinning products and revolutionary packaging. We expect to continue this amazing growth during 2021 as we grow our product catalogue and build our sales team to cater for demand.
To provide an easy access pathway to patients, Sativite has launched an online ePharmacy which allows patients a quick and reliable means to access medicinal cannabis. Here, our trained medical professionals, will assist you in fulfilling your scripts using a convenient online platform – saving you both time and money.
In order to enhance the services and products we offer to you, we are forging ahead with a number of strategic alliances. Here Sativite has secured exclusive distribution rights within the Asia-Pacific region – more to be announced soon…..
Don’t tell anyone, but we are also working on some strategic initiatives which we expect to announce shortly. This will coincide with the release of some exciting new products which are designed to revolutionise the administration and absorption of cannabinoids – a common challenge within our industry.
The Office of Drug Control have advised that our submission for a suite of MC licenses (including RL002/20 (Research), MC017/20 (Cultivation) and ML011/18 (Manufacture)) are progressing within the que and we hope to announce good news on this front soon.
In preparation for this, Sativite has establish greenfield operations within NSW and Queensland and we are currently conducting research into sustainable green-fields cultivations of high CBD Sativa and Indica strains.
Fortunately for Sativite, the global medicinal cannabis industry continues to grow (assisted by recent developments in the USA) and we are confident that our first mover advantage in patient access and scaled production will provide impetus for our planned listing announcement in the future. In the mean-time, Sativite is looking to raise working capital in order to develop our green-fields production and support its
patients access program.
I am also proud to advise that Sativite is working with both State and Federal governments to secure grants to help support regional development and employment opportunities.
On behalf of the Sativite team, I welcome your support during this exciting growth phase and I look forward to updating you on our journey soon…
Chief Executive Officer